CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 81 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $30,298,577 | +286.7% | 1,018,782 | +134.3% | 0.54% | +312.9% |
Q2 2023 | $7,834,519 | +12.2% | 434,768 | 0.0% | 0.13% | +3.1% |
Q1 2023 | $6,982,374 | +89.5% | 434,768 | +80.3% | 0.13% | +132.7% |
Q1 2021 | $3,685,000 | -34.7% | 241,140 | -39.7% | 0.06% | -36.8% |
Q4 2020 | $5,644,000 | -73.3% | 400,000 | -70.3% | 0.09% | -78.9% |
Q3 2020 | $21,107,000 | -10.6% | 1,347,000 | 0.0% | 0.41% | -19.5% |
Q2 2020 | $23,599,000 | +69.5% | 1,347,000 | +42.2% | 0.51% | +13.7% |
Q1 2020 | $13,921,000 | -41.4% | 947,000 | 0.0% | 0.45% | -32.6% |
Q4 2019 | $23,760,000 | +66.8% | 947,000 | 0.0% | 0.67% | +42.0% |
Q3 2019 | $14,243,000 | -29.1% | 947,000 | +17.8% | 0.47% | -22.9% |
Q2 2019 | $20,096,000 | +129.9% | 803,839 | +109.3% | 0.61% | +103.0% |
Q1 2019 | $8,740,000 | +136.5% | 384,000 | +211.6% | 0.30% | +83.5% |
Q4 2018 | $3,696,000 | +4.7% | 123,225 | 0.0% | 0.16% | +26.2% |
Q3 2018 | $3,530,000 | – | 123,225 | – | 0.13% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |